Apalutamide - 2 Phase 3 clinical trials

[alanbarlee]

Apalutamide (JNJ-56021927 formerly known as ARN 509) is a novel small-molecule androgen receptor antagonist similar to enzalutamide but with less central nervous system penetration, which could potentially result in reduced levels of fatigue and seizures.

Curetoday.com has an article about 2 Phase 3 clinical trials of Apalutamide:

• the ATLAS trial (NCT02531516; learn more here);
• the SPARTAN study (NCT01946204; learn more here).

The SPARTAN study is currently recruiting in Australia; the ATLAS study is not.

For SPARTAN, eligible patients must show no signs of evident metastatic prostate cancer and must have a high risk for disease progression.  A high risk for disease progression is defined as either a PSA doubling time (PSADT) of less than 10 months while on continuous ADT, or Castrate Resistant Prostate cancer demonstrated while on continuous ADT.   PSADT is calculated using at least three PSA values during ADT.